Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 951-773-4 | CAS number: -
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2020-11-24 - 2021-04-16
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- Water
- EC Number:
- 231-791-2
- EC Name:
- Water
- Cas Number:
- 7732-18-5
- Molecular formula:
- H2O
- IUPAC Name:
- dihydrogen oxide
- Reference substance name:
- By-product from Guanidinoacetic acid manufacturing
- EC Number:
- 951-773-4
- Molecular formula:
- - Hydantoic Acid Sodium salt: C3H5N2O3Na - Cyanoguanidine: C2H4N4 - Sodium acetate: C3H3O2Na - Glycine: C2H5NO2 - N,N'-Guanidinodiacetic acid: C5H9N3O4 - N,N-Guanidinodiacetic acid: C5H9N3O4 - Guanidinoacetic acid:C3H7N3O2 - Urea: CH4N2O - Water: H2O - Biguanidinoacetic acid: C4H10N6O2 - Sodium formate: CHO2Na - Glycylglycine: C4H8N2O3
- IUPAC Name:
- By-product from Guanidinoacetic acid manufacturing
- Test material form:
- liquid - solid: mixture of
Constituent 1
Constituent 2
- Specific details on test material used for the study:
- 201009MA2 liquid
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl: WI(Han)
- Sex:
- female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- Group 1: 2000 mg / kg bw
Group 2: 2000 mg / kg bw
Based on total dissolved solids in the solution. - No. of animals per sex per dose:
- Group 1: 3 females
Group 2: 3 females - Control animals:
- no
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50 cut-off
- Effect level:
- 5 000 mg/kg bw
- Based on:
- test mat.
- Remarks:
- Total dissolved solids in the solution
- Mortality:
- No
- Clinical signs:
- other: The most relevant clinical findings in the animals were moving the bedding, reduced spontaneous activity, hunched posture and piloerection. The animals recovered within up to one day post-dose.
- Gross pathology:
- No specific gross pathological changes were recorded for any animal.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of the present study, a single oral application of the test item By-product from
Guanidinoacetic acid manufacturing - solution to rats at a dose of 2000 mg/kg body weight (based
on the content of dissolved solids) was associated with signs of toxicity but not with mortality.
The median lethal dose of By-product from Guanidinoacetic acid manufacturing - solution after a
single oral administration to female rats, observed over a period of 14 days is:
LD50 cut-off (rat): 5000 mg/kg bw - Executive summary:
Two groups, each of three female WISTAR Crl: WI(Han) rats, were treated with the test item by oral
gavage administration at a dosage of 2000 mg/kg body weight. The liquid test item was applied
undiluted. The dose was calculated based on the content of dissolved solids in aqueous solution
(18.03%).
All animals used in the study after their entrance at BSL were allowed to acclimatise to the
laboratory conditions for at least 5 days. The animals were observed on delivery, on inclusion in the
study and before administration for mortality/morbidity and other clinical signs. All animals were
examined for clinical signs several times on the day of dosing and once daily until the end of the
observation period. Their body weights were recorded on day 1 (prior to the administration) and on
days 8 and 15. All animals were necropsied and examined macroscopically.All animals survived until the end of the study showing slight to moderate signs of toxicity.
The most relevant clinical findings in the animals were moving the bedding, reduced spontaneous
activity, hunched posture and piloerection. All animals recovered within up to one day post-dose.
Throughout the 14-day observation period, the weight gain of the animals was within the normal
range of variation for this strain.
At necropsy, no macroscopic findings were observed in any animal of any step.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
